GRN163L FOR USE AS TELOMERASE INHIBITOR IN THE TREATMENT OF CANCER

摘要

The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.